These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 34812049)

  • 41. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2: basic concepts, origin and treatment advances.
    Santos-López G; Cortés-Hernández P; Vallejo-Ruiz V; Reyes-Leyva J
    Gac Med Mex; 2021; 157(1):84-89. PubMed ID: 34125824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Looking beyond COVID-19 vaccine phase 3 trials.
    Kim JH; Marks F; Clemens JD
    Nat Med; 2021 Feb; 27(2):205-211. PubMed ID: 33469205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing the impact of vaccination strategies on the spread of COVID-19, including a novel household-targeted vaccination strategy.
    Voigt A; Omholt S; Almaas E
    PLoS One; 2022; 17(2):e0263155. PubMed ID: 35108311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
    Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
    Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
    Raman R; Patel KJ; Ranjan K
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy.
    Narożna M; Rubiś B
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.
    Ramezankhani R; Solhi R; Memarnejadian A; Nami F; Hashemian SMR; Tricot T; Vosough M; Verfaillie C
    Int J Antimicrob Agents; 2020 Dec; 56(6):106208. PubMed ID: 33213829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice.
    Paschall AV; Ozdilek A; Briner SL; Brindley MA; Avci FY
    Vaccine; 2022 Feb; 40(6):854-861. PubMed ID: 34991929
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Update to living systematic review on drug treatments for covid-19.
    BMJ; 2021 Mar; 372():n858. PubMed ID: 33789885
    [No Abstract]   [Full Text] [Related]  

  • 55. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges of vaccination and herd immunity in COVID-19 and management strategies.
    She J; Hou D; Chen C; Bi J; Song Y
    Clin Respir J; 2022 Nov; 16(11):708-716. PubMed ID: 36172975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.
    Muralidar S; Ambi SV; Sekaran S; Krishnan UM
    Biochimie; 2020 Dec; 179():85-100. PubMed ID: 32971147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SARS-CoV-2-specific T cells in infection and vaccination.
    Bertoletti A; Le Bert N; Qui M; Tan AT
    Cell Mol Immunol; 2021 Oct; 18(10):2307-2312. PubMed ID: 34471260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection.
    Pei R; Feng J; Zhang Y; Sun H; Li L; Yang X; He J; Xiao S; Xiong J; Lin Y; Wen K; Zhou H; Chen J; Rong Z; Chen X
    Protein Cell; 2021 Sep; 12(9):717-733. PubMed ID: 33314005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.